Hyloris: authorities request access to documents during headquarters visit, listing briefly suspended this morning
The Belgian pharmaceutical laboratory, listed on Euronext Brussels, indicated that this action concerns access to certain documents related to historical files that have already been the subject of exchanges with the FSMA.
In a statement published on October 15, 2026, Hyloris Pharmaceuticals confirmed that representatives of the authorities visited its offices in Liège on October 14, 2026. During this visit, the authorities requested access to certain documents.
According to the company, this request is related to prior files that have already given rise to exchanges with the FSMA. The group specifies that the underlying facts and circumstances are not new.
Hyloris states it is cooperating fully and continuing its operations
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Hyloris indicated that it continues to cooperate with the authorities and committed to informing the market when new information becomes available. The company reaffirmed its commitment to transparency, responsible governance and compliance with applicable regulations.
The group, specializing in the reformulation of existing medicines, also clarified that its daily activities continue normally. It emphasizes the execution of its strategy, its ongoing development programs and its commercial activities.
After being suspended around 9:30 a.m. this morning, trading resumed around 11 a.m.
Related
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 4,7 millions d'euros
Quarterly revenue: 4,7 millions d'euros
Net income: -1,9 millions d'euros
Guidance from the release
« After the reporting date, the Chief Executive Officer … issued a comfort letter … financial support up to a maximum amount of €2.5 million until 30 September 2027 » ; « this support extends the Company's cash runway into the fourth quarter of 2027 » ; « management has not identified any material uncertainties »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
